Clinical Implications of Portal Hypertension

Introduction to Portal Hypertension

Portal hypertension leads to life-threatening complications, including variceal bleeding, ascites, hepatorenal syndrome, and hepatic encephalopathy, making it the most important cause of morbidity and mortality in patients with cirrhosis, with a 30-day mortality of 20% and reducing 5-year survival from 80% to 50% 1, 2

The American College of Radiology defines portal hypertension severity by hepatic venous pressure gradient (HVPG) measurements, with normal HVPG being 1-5 mmHg, portal hypertension being HVPG ≥6 mmHg, and clinically significant portal hypertension (CSPH) being HVPG ≥10 mmHg, at which point complications such as esophageal varices and ascites develop 1, 2, 3
The high mortality threshold is HVPG ≥16 mmHg, which is independently associated with higher mortality in both compensated and decompensated cirrhosis 1, 3

The American College of Radiology recommends immediate management of variceal bleeding with combination therapy, including early initiation of vasoactive agents plus endoscopic therapy, which controls bleeding in up to 85% of patients 1, 3
Ascites reduces 5-year survival from 80% in compensated cirrhosis to 50% when ascites appears, and refractory ascites has a 1-year mortality ranging from 20% to 50% 1, 2, 4
Hepatorenal syndrome (HRS) is a frequent and grave complication of refractory ascites, triggered by arterial vasodilation in the splanchnic circulation, with HRS Type 1 showing progressive, severe decline in renal function and HRS Type 2 demonstrating more constant renal dysfunction 1, 3

Clinically significant portal hypertension (HVPG >10 mmHg) and Child-Pugh class B cirrhosis represent absolute contraindications to major liver resections (>2 segments), as portal hypertension is a major predictor of post-hepatectomy liver failure, perioperative mortality, and long-term survival 6

The American College of Radiology recommends monitoring HVPG reduction of ≥20% from baseline or to <12 mmHg, which correlates with considerable reduction in variceal bleeding risk during treatment with non-selective beta blockers 1, 3
HVPG-guided therapy has been shown to reduce portal hypertension-related decompensations and mortality 5

The American Association for the Study of Liver Diseases recommends considering liver transplantation in all patients with decompensated cirrhosis as definitive treatment, and transjugular intrahepatic portosystemic shunt (TIPS) is indicated for refractory variceal bleeding and refractory ascites 2, 4